Immunotherapy of malignant melanoma

Surgical Clinics of North America

Volumn 83, Issue 2, 2003, Pages 343-370

  Kadison, Alan S ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC CELL LYSATE VACCINE; ALPHA2B INTERFERON; ANTIIDIOTYPE VACCINE; AUTOLOGOUS WHOLE CELL VACCINE; BCG VACCINE; CANCER VACCINE; CANVAXIN PV; CELLULAR VACCINE; CYTOKINE; DACARBAZINE; DENDRITIC CELL VACCINE; DNA VACCINE; GANGLIOSIDE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; IMMUNOCYTOKINE; INTERLEUKIN 2; LYSATE VACCINE; M VAX; MELANOMA VACCINE; PEPTIDE VACCINE; PURIFIED PROTEIN VACCINE; RNA VACCINE; SHED ANTIGEN VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE; VIRUS ONCOLYSATE;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG DESIGN; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOGENICITY; MEDICAL DECISION MAKING; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE POLYMERASE CHAIN REACTION; REVIEW; TUMOR HOST INTERACTION;

CANCER VACCINES; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037398411     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00162-7     Document Type: Review

References (153)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23.
2. Morton DL, Ollila DW, Hsueh EC, et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 1999;49:101.
3. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463.
4. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996; 46:225.
5. Kawakami Y, Suzuki Y, Shofuda T, et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res 2000;13:163.
6. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643.
7. Adema GJ, de Boer AJ, Vogel AM, et al. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 1994;269:20126.
8. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489.
9. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515.
10. Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006.
11. Benjamini E. Immunology - a short course. 4th edition. New York: Wiley-Liss; 2000.
12. Rich RR. Clinical immunology, principles and practice. St. Louis: Mosby-Year Book, Inc.; 1996.
13. Hudrisier D, Kessler B, Valitutti S, et al. The efficiency of antigen recognition by CD8 + CTL clones is determined by the frequency of serial TCR engagement. J Immunol 1998; 161:553.
14. Labarriere N, Diez E, Pandolfino MC, et al. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 1997;158:1238.
15. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75:517.
16. Jager E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71:142.
17. DeMars R, Rudersdorf R, Chang C, et al. Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. Proc Natl Acad Sci USA 1985;82:8183.
18. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225.
19. Chen Q, Daniel V, Maher DW, et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56:755.
20. Dummer W, Bastian BC, Ernst N, et al. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996;66:607.
21. Conrad CT, Ernst NR, Dummer W, et al. Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res 1999;18:225.
22. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915.
23. Steinbrink K, Wolff M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772.
24. Buelens C, Willems F, Delvaux A, et al. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995;25:2668.
25. Caux C, Massacrier C, Vanbervliet B, et al. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol 1994;6:1177.
26. Macatonia SE, Doherty TM, Knight SC, et al. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J Immunol 1993;150: 3755.
27. Peguet-Navarro J, Moulon C, Caux C, et al. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol 1994;24:884.
28. Steinbrink K, Jonuleit H, Muller G, et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634.
29. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096.
30. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778.
31. Morton DL, Holmes EC, Golub SH. Immunologic aspects of lung cancer. Chest 1977; 71:640.
32. Nauts H. A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man. Acta Med Scand Suppl 1953;276:1.
33. Morton D, Eilber FR, Malmgren RA, et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158.
34. Morton DL, Malmgren RA, Holmes EC, et al. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968;64:233.
35. Mukherji B, Wilhelm SA, Guha A, et al. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 1986;136:1888.
36. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491.
37. Gupta RK, Relyveld EH, Lindblad EB, et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993;11:293.
38. Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974;180:635.
39. Czarnetzki BM, Macher E, Suciu S, et al. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993; 9:1237.
40. Knight BC, Souberbielle BE, Rizzardi GP, et al. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996;6:299.
41. Toes RE, Blom RJ, van der Voort E, et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996;56:3782.
42. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 1998;25:611.
43. Bystryn J-C. Shedding and degradation of cell-surface macromolecules and tumor-associated antigens by human melanoma. New York: Plenum Press; 1982.
44. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882.
45. Bystryn JC. Vaccines for melanoma. Design strategies and clinical results. Dermatol Clin 1998;16:269.
46. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69.
47. Lindenmann J, Klein PA. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 1967;126:93.
48. Wallack MK, Sivanandham M, Ditaranto K, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997;226:198.
49. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623.
50. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321.
51. Tsai V, Southwood S, Sidney J, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997;158:1796.
52. Ritter G, Ritter-Boosfeld E, Adluri R, et al. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 1995;62:668.
53. Ravindranath MH, Morton DL. Role of gangliosides in active immunotherapy with melanoma vaccine. Int Rev Immunol 1991;7:303.
54. Irie RF, Giuliano AE, Morton DL. Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man. J Natl Cancer Inst 1979;63:367.
55. Irie RF, Irie K, Morton DL. A membrane antigen common to human cancer and fetal brain tissues. Cancer Res 1976;36:3510.
56. Tai T, Paulson JC, Cahan LD, et al. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci USA 1983;80:5392.
57. Cahan LD, Irie RF, Singh R, et al. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982;79:7629.
58. Tai T, Cahan LD, Tsuchida T, et al. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985;35:607.
59. Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981;66:249.
60. Livingston P, Zhang S, Adluri S, et al. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 1997;43:324.
61. Lee SW, Li H, Strong TV, et al. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials. J Immunother 2000;23:379.
62. Nawrath M, Pavlovic J, Moelling K. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J Mol Med 2001;79:133.
63. Park JH, Kim CJ, Lee JH, et al. Effective immunotherapy of cancer by DNA vaccination. Mol Cells 1999;9:384.
64. Schultz J, Pavlovic J, Moelling K. Immune modulation in cancer using DNA inoculation-antitumour effect of interleukin-12. Dev Biol 2000;104:109.
65. Sun X, Hodge LM, Jones HP, et al. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 2002;20:1466.
66. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341.
67. Fujii H, Inobe M, Kimura F, et al. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int J Cancer 1996;66:219.
68. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767.
69. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162:168.
70. Larsson M, Messmer D, Somersan S, et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8 + T cells. J Immunol 2000;165:1182.
71. Kukutsch NA, Rossner S, Austyn JM, et al. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J Invest Dermatol 2000;115:449.
72. Nair SK, Hull S, Coleman D, et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing. Int J Cancer 1999;82:121.
73. Hoffmann TK, Nakano K, Elder EM, et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000;165:5938.
74. Chakraborty NG, Sporn JR, Tortora AF, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting cell-based vaccine in melanoma. Cancer Immunol Immunother 1998;47:58.
75. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86.
76. Chang JW, Peng M, Vaquerano JE, et al. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res 2000;20:1329.
77. Hoffmann TK, Meidenbauer N, Dworacki G, et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542.
78. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332.
79. Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516.
80. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998;161:5607.
81. Zhong L, Granelli-Piperno A, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29:964.
82. Hoon DS, Wang Y, Sze L, et al. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res 1993;53:5244.
83. Nishinaka Y, Ravindranath MH, Irie RF. Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Cancer Res 1996;56:5666.
84. Kjaergaard J, Peng L, Cohen PA, et al. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001;167:6669.
85. Brown CK, Kirkwood JM. Targeted therapy for malignant melanoma. Curr Oncol Rep 2001;3:344.
86. Conlon KC, Anver MR, Longo DL, et al. Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts. J Immunother Emphasis Tumor Immunol 1996;19:317.
87. Lode HN, Xiang R, Pertl U, et al. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest 2000; 105:1623.
88. Becker JC, Pancook JD, Gillies SD, et al. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996;93:2702.
89. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318.
90. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363.
91. Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002; 20:1075.
92. Menoret A, Chandawarkar R. Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Semin Oncol 1998;25:654.
93. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117.
94. Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001;61:222.
95. Cheresh DA, Reisfeld RA, Varki AP. O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 1984;225:844.
96. Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997;150:2143.
97. Doi F, Chi DD, Charuworn BB, et al. Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer 1996;65:454.
98. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247.
99. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921.
100. Gupta RK, Morton DL. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst 1983;70:993.
101. Gupta RK, Morton DL. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. III. Physicochemical properties. J Natl Cancer Inst 1984;72:83.
102. Hoon DS, Yuzuki D, Hayashida M, et al. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154:730.
103. Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913.
104. Huang SK, Okamoto T, Morton DL, et al. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 1998;111:662.
105. Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437.
106. Morioka N, Kikumoto Y, Hoon DS, et al. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994;153:5650.
107. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998;111:1034.
108. Ravindranath MH, Amiri AA, Bauer PM, et al. Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Cancer 1997;79:1686.
109. Ravindranath MH, Morton DL, Irie RF. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 1989;49:3891.
110. Ravindranath MH, Tsuchida T, Morton DL, et al. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991;67:3029.
111. Sarantou T, Chi DD, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997;57:1371.
112. Takahashi T, Conforti A, Kikumoto Y, et al. Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine. J Clin Immunol 1998; 18:299.
113. Tsuchida T, Saxton RE, Irie RF. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 1987;78:55.
114. Tsuchida T, Saxton RE, Morton DL, et al. Gangliosides of human melanoma. Cancer 1989;63:1166.
115. Wong JH, Aguero B, Gupta RK, et al. Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients. Cancer Immunol Immunother 1988; 27:142.
116. Wong JH, Xu SH, Gupta RK, et al. Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma. Arch Surg 1990;125:187.
117. Hsueh EC, Gupta RK, Yee R, et al. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol 2000;7:232.
118. Morton DL, Nizze A, Hoon D, et al. Improved survival of advanced stage IV melanoma following active immunotherapy; Correlation with immune response to melanoma vaccine. Proc Am Soc Clin Oncol 1993;12.
119. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20:45-49.
120. Barth A, Hoon DS, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54:3342.
121. Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg, 2002;263:438.
122. DiFronzo LA, Gupta RK, Essner R, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002; 20:3242.
123. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444.
124. Berd D, Maguire HC Jr, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359.
125. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2002;2:335.
126. Berd D, Sato T, Cohn H, et al. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001;94:531.
127. Wallack MK, McNally K, Michaelides M, et al. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). Am Surg 1986;52:148.
128. Wallack MK, Scoggin SD, Sivanandham M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med 1992;59:227.
129. Hersey P. Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann N Y Acad Sci 1993;690:167.
130. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 1992;16:251.
131. Elliott GT, McLeod RA, Perez J, et al. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993; 9:264.
132. Bystryn JC, Oratz R, Roses D, et al. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992; 69:1157.
133. Steitz J, Bruck J, Steinbrink K, et al. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000;86:89.
134. Miller K, Abeles G, Oratz R, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995;75:495.
135. Salgaller ML, Marincola FM, Cormier JN, et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749.
136. Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987;84:2911.
137. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036.
138. Kitamura K, Livingston PO, Fortunato SR, et al. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 1995;92:2805.
139. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370.
140. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49:7045.
141. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297.
142. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317.
143. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328.
144. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24:66.
145. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669.
146. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1):S11.
147. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907.
148. Leong SP, Enders-Zohr P, Zhou YM, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999; 22:166.
149. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614.
150. Quan WD Jr, Dean GE, Spears L, et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 1997;15:2103.
151. McCaffery M, Yao TJ. Williams L. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996;2:679.
152. Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000;18:376.
153. Alfonso M, Diaz A, Hernandez AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168:2523.